I'm essentially with Vin and 4Seasons on this one. The review can work both ways. It prudently protects Teva's bottom line but is also a great opportunity to fast track. What I am more sceptical about is the time-frame. I'd be surprised if the review takes place as early as 1st quarter 2014 as I'd imagine they would need to follow up on these early patients for at least 6 or 12 months. This is still "early" as a full Phase III normally takes about 3 years. I, of course, hope I'm wrong and that an even earlier review shows such compelling evidence of efficacy that the road to market is fast-tracked but I think we should avoid seeing a delay as bad news.
I'm essentially with Vin and 4Seasons on this one. The review...
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.07 |
Change
-0.055(4.89%) |
Mkt cap ! $1.221B | |||
| Open | High | Low | Value | Volume |
| $1.14 | $1.16 | $1.06 | $8.816M | 8.055M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 280000 | $1.07 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.07 | 2000 | 1 |
View Market Depth
| Last trade - 16.10pm 29/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |